Ready 8-Ks
4
Latest filing
August 25, 2026, 7:28 PM ET
Top materiality
0.75
Event mix
earnings ×2 · other_material ×1 · other ×1
Sentiment
1 pos · 1 neg · 2 neu
Latest earnings
reported 2026-Q2
Recent 8-K filings for GENB
Highest-materiality recent filing
Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control
- Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.
- COPD Part C (N=40): biomarker reductions from Month 1 sustained ≥6 months; 300 mg comparable to 600 mg; no related SAEs.
-
Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control
Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.
-
Generate Q1 net loss widens to $61.7M, cash $516.6M post-IPO; pipeline advances
Net loss $61.7M vs $44.3M YoY; revenue $7.2M (down 18% from $8.8M).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.60 · Most common event earnings